Rx Medicare

NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (http://www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

Read More…

Related Posts

• NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
• Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza
• Implications Of Influenza Pandemics On Blood Supplies Highlighted By Study
• Vaccination, Antivirals And Social Distancing May Blunt Impact Of H1N1 Influenza, Finds Epidemiological Modelling Study
• SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus In Initial Pilot Animal Study
• Previous Flu Viruses Provided Some Immunity To Current Swine Flu, Study Shows
• New Study Evaluates Surgical Masks Vs. N95 Respirators For Preventing Influenza Among Health Care Workers
• NanoViricides Platform Enables Rapid Development Of Robust Nanomedicines Against Influenza And HIV
• Most Appropriate Treatment Strategy: Extension Of Vaccination Policy Or Prescription Of Anti-Influenza For Healthy Adults?
• Amarillo Biosciences Announces Completion Of Screening Process For Influenza Study In Australia
• Study Documents Increasing Prevalence Of Influenza A Resistance To Drug Oseltamivir
• Authoritative New Study Reveals Global Pandemic Influenza Vaccine Capacity
• Workplace Benefits Of Influenza Vaccination In 50-64 Year Olds Shown By Study

Tags: animal, congress, current, data, efficacy, flucide%e2%84%a2, improved, influenza, nanoviricides, presents, study, substantially, superior, treatment, vastly

This entry was posted on Thursday, November 26th, 2009 at 1:11 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.